Landgren Ola, Linet Martha S, McMaster Mary L, Gridley Gloria, Hemminki Kari, Goldin Lynn R
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Int J Cancer. 2006 Jun 15;118(12):3095-8. doi: 10.1002/ijc.21745.
A population-based case-control study was conducted to evaluate risk of developing multiple myeloma (MM) associated with personal history of autoimmune diseases and occurrence of autoimmune and selected hematologic disorders in first-degree relatives. Data were obtained for all (n = 8,406) MM cases diagnosed in Sweden (1958-1998), with linkable relatives, 16,543 matched controls and first-degree relatives of cases (n = 22,490) and controls (n = 44,436). Odds ratios (ORs) were calculated to quantify the risk of MM in relation to personal/family history of 32 autoimmune disorders. Familial aggregation of malignancies was evaluated in a marginal survival model using relatives as the cohort. The risk for MM was significantly elevated among subjects with a personal history of pernicious anemia (OR = 3.27; 2.22-4.83) and individuals with a family history of systemic lupus erythematosus (OR = 2.66; 1.12-6.32). Compared with controls, relative risk (RR) of MM was significantly increased (RR = 1.67; 1.02-2.73) in relatives of cases, particularly relatives of probands aged > or =65 at diagnosis (RR = 2.50; 1.19-5.27). Risks were nearly 4-fold elevated among female relatives (RR = 3.97; 1.54-10.2) and among relatives of female probands (RR = 3.74; 1.58-8.83). MM cases had more cases of monoclonal gammopathy of undetermined significance (MGUS) among their relatives than controls, but the numbers were too small to be conclusive. There was generally no increase in risk of MM in probands whose relatives had hematologic malignancies other than MM. These findings do not support a strong association between personal/familial autoimmune diseases and MM. However, MM itself shows significant familial aggregation, implicating the etiologic importance of this type of hematological neoplasm and perhaps MGUS in germ line genes.
开展了一项基于人群的病例对照研究,以评估自身免疫性疾病个人史以及一级亲属中自身免疫性疾病和特定血液系统疾病的发生与患多发性骨髓瘤(MM)风险之间的关系。获取了瑞典(1958 - 1998年)诊断的所有(n = 8406)MM病例的数据,这些病例有可关联的亲属、16543名匹配对照以及病例(n = 22490)和对照(n = 44436)的一级亲属。计算比值比(OR)以量化与32种自身免疫性疾病的个人/家族史相关的MM风险。在一个边缘生存模型中,以亲属作为队列评估恶性肿瘤的家族聚集性。恶性贫血个人史患者中MM风险显著升高(OR = 3.27;2.22 - 4.83),系统性红斑狼疮家族史个体中MM风险也显著升高(OR = 2.66;1.12 - 6.32)。与对照相比,病例亲属中MM的相对风险(RR)显著增加(RR = 1.67;1.02 - 2.73),尤其是诊断时年龄≥65岁的先证者的亲属(RR = 2.50;1.19 - 5.27)。女性亲属(RR = 3.97;1.54 - 10.2)以及女性先证者的亲属(RR = 3.74;1.58 - 8.83)中的风险升高近4倍。MM病例的亲属中意义未明的单克隆丙种球蛋白病(MGUS)病例比对照更多,但数量太少无法得出结论。亲属患有除MM之外的血液系统恶性肿瘤的先证者中,MM风险通常没有增加。这些发现不支持个人/家族自身免疫性疾病与MM之间存在强关联。然而,MM本身显示出显著的家族聚集性,这表明这类血液肿瘤以及可能的MGUS在种系基因中的病因学重要性。